[
  {
    "sentence": "Using the population-based linked Surveillance, Epidemiology, and End Results (SEER)-Medicare registry, we selected fee-for-service Medicare beneficiaries with acute or chronic leukemias, multiple myeloma, myeloproliferative neoplasms, myelodysplastic syndrome, and all subtypes of lymphoma who were diagnosed at age 66 years or older, who died between 2008 and 2015 with a cause of death ascribed to the hematologic malignancy, and who had ≥30 days of observed survival since diagnosis (Figure 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "These constructs (Figure 2B) were determined using claims within 30 days before hospice enrollment for those who used hospice services and within 30 days before death for decedents not enrolled in hospice, as previously described.12\nFigure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm.Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Adjusted risk ratios (RR) and means ratios are from multivariable models in the aggregate cohort of all histologies, adjusting for age, sex, race/ethnicity, socioeconomic status, comorbidities, performance status, survival from diagnosis, and temporal trends.From inpatient and outpatient Medicare claims, we then ascertained 3 previously described indicators of aggressive EOL care: death in an acute care hospital, ICU admission in the last 30 days of life, and chemotherapy administration in the last 14 days of life (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Use of hospice services was significantly associated with indicators of higher palliative needs, including prescriptions for opioids (adjusted RR, 1.40; 95% CI, 1.34-1.47), administration of blood transfusions (adjusted RR, 1.32; 95% CI, 1.26-1.38), and mean number of physician visits (adjusted means ratio, 1.21; 95% CI, 1.18-1.24) within 30 days before hospice enrollment or death (supplemental Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "We observed a significant increase in the proportion of beneficiaries enrolled in hospice before death between 2008 and 2015 (P < .001), and a significant decrease in the proportion dying in the acute care hospital (P < .001; Figure 1C).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel C",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "However, there also was a significant increase in patients with ICU admissions at the EOL (P < .001) but no significant change in the proportion receiving chemotherapy at the EOL, in the hospice LOS, or in the median number of days spent in the hospital during the last month of life (Figure 1D).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "These trends were generally consistent across histologies, although we observed a significant increase in the use of chemotherapy at EOL in myeloma (P < .001) and a decreased hospice LOS in leukemia and myeloma (supplemental Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The measures of EOL care differed between hospice enrollees and nonenrollees, with hospice enrollees being consistently less likely to receive aggressive modalities of care at the EOL (Figure 2A-C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "These associations were consistent across major histology groups, as studied in select common specific histologies: acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, and aggressive and indolent non-Hodgkin lymphomas (supplemental Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Furthermore, across all histologies, hospice enrollees had fewer inpatient days in the last 30 days of life and lower Medicare spending (Figure 2D-E), with an average 41% decrease in the number of inpatient days (adjusted means ratio, 0.59; 95% CI, 0.57-0.60) and a 38% decrease in mean Medicare spending (adjusted means ratio, 0.62; 95% CI, 0.61-0.64).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Using the population-based linked Surveillance, Epidemiology, and End Results (SEER)-Medicare registry, we selected fee-for-service Medicare beneficiaries with acute or chronic leukemias, multiple myeloma, myeloproliferative neoplasms, myelodysplastic syndrome, and all subtypes of lymphoma who were diagnosed at age 66 years or older, who died between 2008 and 2015 with a cause of death ascribed to the hematologic malignancy, and who had ≥30 days of observed survival since diagnosis (Figure 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "These constructs (Figure 2B) were determined using claims within 30 days before hospice enrollment for those who used hospice services and within 30 days before death for decedents not enrolled in hospice, as previously described.12\nFigure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm.Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Adjusted risk ratios (RR) and means ratios are from multivariable models in the aggregate cohort of all histologies, adjusting for age, sex, race/ethnicity, socioeconomic status, comorbidities, performance status, survival from diagnosis, and temporal trends.From inpatient and outpatient Medicare claims, we then ascertained 3 previously described indicators of aggressive EOL care: death in an acute care hospital, ICU admission in the last 30 days of life, and chemotherapy administration in the last 14 days of life (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Use of hospice services was significantly associated with indicators of higher palliative needs, including prescriptions for opioids (adjusted RR, 1.40; 95% CI, 1.34-1.47), administration of blood transfusions (adjusted RR, 1.32; 95% CI, 1.26-1.38), and mean number of physician visits (adjusted means ratio, 1.21; 95% CI, 1.18-1.24) within 30 days before hospice enrollment or death (supplemental Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "We observed a significant increase in the proportion of beneficiaries enrolled in hospice before death between 2008 and 2015 (P < .001), and a significant decrease in the proportion dying in the acute care hospital (P < .001; Figure 1C).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel C",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "However, there also was a significant increase in patients with ICU admissions at the EOL (P < .001) but no significant change in the proportion receiving chemotherapy at the EOL, in the hospice LOS, or in the median number of days spent in the hospital during the last month of life (Figure 1D).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "These trends were generally consistent across histologies, although we observed a significant increase in the use of chemotherapy at EOL in myeloma (P < .001) and a decreased hospice LOS in leukemia and myeloma (supplemental Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The measures of EOL care differed between hospice enrollees and nonenrollees, with hospice enrollees being consistently less likely to receive aggressive modalities of care at the EOL (Figure 2A-C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "These associations were consistent across major histology groups, as studied in select common specific histologies: acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, and aggressive and indolent non-Hodgkin lymphomas (supplemental Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Furthermore, across all histologies, hospice enrollees had fewer inpatient days in the last 30 days of life and lower Medicare spending (Figure 2D-E), with an average 41% decrease in the number of inpatient days (adjusted means ratio, 0.59; 95% CI, 0.57-0.60) and a 38% decrease in mean Medicare spending (adjusted means ratio, 0.62; 95% CI, 0.61-0.64).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Using the population-based linked Surveillance, Epidemiology, and End Results (SEER)-Medicare registry, we selected fee-for-service Medicare beneficiaries with acute or chronic leukemias, multiple myeloma, myeloproliferative neoplasms, myelodysplastic syndrome, and all subtypes of lymphoma who were diagnosed at age 66 years or older, who died between 2008 and 2015 with a cause of death ascribed to the hematologic malignancy, and who had ≥30 days of observed survival since diagnosis (Figure 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "These constructs (Figure 2B) were determined using claims within 30 days before hospice enrollment for those who used hospice services and within 30 days before death for decedents not enrolled in hospice, as previously described.12\nFigure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm.Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Adjusted risk ratios (RR) and means ratios are from multivariable models in the aggregate cohort of all histologies, adjusting for age, sex, race/ethnicity, socioeconomic status, comorbidities, performance status, survival from diagnosis, and temporal trends.From inpatient and outpatient Medicare claims, we then ascertained 3 previously described indicators of aggressive EOL care: death in an acute care hospital, ICU admission in the last 30 days of life, and chemotherapy administration in the last 14 days of life (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Use of hospice services was significantly associated with indicators of higher palliative needs, including prescriptions for opioids (adjusted RR, 1.40; 95% CI, 1.34-1.47), administration of blood transfusions (adjusted RR, 1.32; 95% CI, 1.26-1.38), and mean number of physician visits (adjusted means ratio, 1.21; 95% CI, 1.18-1.24) within 30 days before hospice enrollment or death (supplemental Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "We observed a significant increase in the proportion of beneficiaries enrolled in hospice before death between 2008 and 2015 (P < .001), and a significant decrease in the proportion dying in the acute care hospital (P < .001; Figure 1C).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel C",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "However, there also was a significant increase in patients with ICU admissions at the EOL (P < .001) but no significant change in the proportion receiving chemotherapy at the EOL, in the hospice LOS, or in the median number of days spent in the hospital during the last month of life (Figure 1D).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "These trends were generally consistent across histologies, although we observed a significant increase in the use of chemotherapy at EOL in myeloma (P < .001) and a decreased hospice LOS in leukemia and myeloma (supplemental Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The measures of EOL care differed between hospice enrollees and nonenrollees, with hospice enrollees being consistently less likely to receive aggressive modalities of care at the EOL (Figure 2A-C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "These associations were consistent across major histology groups, as studied in select common specific histologies: acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, and aggressive and indolent non-Hodgkin lymphomas (supplemental Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Furthermore, across all histologies, hospice enrollees had fewer inpatient days in the last 30 days of life and lower Medicare spending (Figure 2D-E), with an average 41% decrease in the number of inpatient days (adjusted means ratio, 0.59; 95% CI, 0.57-0.60) and a 38% decrease in mean Medicare spending (adjusted means ratio, 0.62; 95% CI, 0.61-0.64).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Using the population-based linked Surveillance, Epidemiology, and End Results (SEER)-Medicare registry, we selected fee-for-service Medicare beneficiaries with acute or chronic leukemias, multiple myeloma, myeloproliferative neoplasms, myelodysplastic syndrome, and all subtypes of lymphoma who were diagnosed at age 66 years or older, who died between 2008 and 2015 with a cause of death ascribed to the hematologic malignancy, and who had ≥30 days of observed survival since diagnosis (Figure 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "These constructs (Figure 2B) were determined using claims within 30 days before hospice enrollment for those who used hospice services and within 30 days before death for decedents not enrolled in hospice, as previously described.12\nFigure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm.Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Adjusted risk ratios (RR) and means ratios are from multivariable models in the aggregate cohort of all histologies, adjusting for age, sex, race/ethnicity, socioeconomic status, comorbidities, performance status, survival from diagnosis, and temporal trends.From inpatient and outpatient Medicare claims, we then ascertained 3 previously described indicators of aggressive EOL care: death in an acute care hospital, ICU admission in the last 30 days of life, and chemotherapy administration in the last 14 days of life (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Use of hospice services was significantly associated with indicators of higher palliative needs, including prescriptions for opioids (adjusted RR, 1.40; 95% CI, 1.34-1.47), administration of blood transfusions (adjusted RR, 1.32; 95% CI, 1.26-1.38), and mean number of physician visits (adjusted means ratio, 1.21; 95% CI, 1.18-1.24) within 30 days before hospice enrollment or death (supplemental Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "We observed a significant increase in the proportion of beneficiaries enrolled in hospice before death between 2008 and 2015 (P < .001), and a significant decrease in the proportion dying in the acute care hospital (P < .001; Figure 1C).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel C",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "However, there also was a significant increase in patients with ICU admissions at the EOL (P < .001) but no significant change in the proportion receiving chemotherapy at the EOL, in the hospice LOS, or in the median number of days spent in the hospital during the last month of life (Figure 1D).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "These trends were generally consistent across histologies, although we observed a significant increase in the use of chemotherapy at EOL in myeloma (P < .001) and a decreased hospice LOS in leukemia and myeloma (supplemental Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The measures of EOL care differed between hospice enrollees and nonenrollees, with hospice enrollees being consistently less likely to receive aggressive modalities of care at the EOL (Figure 2A-C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "These associations were consistent across major histology groups, as studied in select common specific histologies: acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, and aggressive and indolent non-Hodgkin lymphomas (supplemental Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Furthermore, across all histologies, hospice enrollees had fewer inpatient days in the last 30 days of life and lower Medicare spending (Figure 2D-E), with an average 41% decrease in the number of inpatient days (adjusted means ratio, 0.59; 95% CI, 0.57-0.60) and a 38% decrease in mean Medicare spending (adjusted means ratio, 0.62; 95% CI, 0.61-0.64).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Using the population-based linked Surveillance, Epidemiology, and End Results (SEER)-Medicare registry, we selected fee-for-service Medicare beneficiaries with acute or chronic leukemias, multiple myeloma, myeloproliferative neoplasms, myelodysplastic syndrome, and all subtypes of lymphoma who were diagnosed at age 66 years or older, who died between 2008 and 2015 with a cause of death ascribed to the hematologic malignancy, and who had ≥30 days of observed survival since diagnosis (Figure 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "These constructs (Figure 2B) were determined using claims within 30 days before hospice enrollment for those who used hospice services and within 30 days before death for decedents not enrolled in hospice, as previously described.12\nFigure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm.Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Adjusted risk ratios (RR) and means ratios are from multivariable models in the aggregate cohort of all histologies, adjusting for age, sex, race/ethnicity, socioeconomic status, comorbidities, performance status, survival from diagnosis, and temporal trends.From inpatient and outpatient Medicare claims, we then ascertained 3 previously described indicators of aggressive EOL care: death in an acute care hospital, ICU admission in the last 30 days of life, and chemotherapy administration in the last 14 days of life (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Use of hospice services was significantly associated with indicators of higher palliative needs, including prescriptions for opioids (adjusted RR, 1.40; 95% CI, 1.34-1.47), administration of blood transfusions (adjusted RR, 1.32; 95% CI, 1.26-1.38), and mean number of physician visits (adjusted means ratio, 1.21; 95% CI, 1.18-1.24) within 30 days before hospice enrollment or death (supplemental Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "We observed a significant increase in the proportion of beneficiaries enrolled in hospice before death between 2008 and 2015 (P < .001), and a significant decrease in the proportion dying in the acute care hospital (P < .001; Figure 1C).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel C",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "However, there also was a significant increase in patients with ICU admissions at the EOL (P < .001) but no significant change in the proportion receiving chemotherapy at the EOL, in the hospice LOS, or in the median number of days spent in the hospital during the last month of life (Figure 1D).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "These trends were generally consistent across histologies, although we observed a significant increase in the use of chemotherapy at EOL in myeloma (P < .001) and a decreased hospice LOS in leukemia and myeloma (supplemental Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The measures of EOL care differed between hospice enrollees and nonenrollees, with hospice enrollees being consistently less likely to receive aggressive modalities of care at the EOL (Figure 2A-C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "These associations were consistent across major histology groups, as studied in select common specific histologies: acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, and aggressive and indolent non-Hodgkin lymphomas (supplemental Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Furthermore, across all histologies, hospice enrollees had fewer inpatient days in the last 30 days of life and lower Medicare spending (Figure 2D-E), with an average 41% decrease in the number of inpatient days (adjusted means ratio, 0.59; 95% CI, 0.57-0.60) and a 38% decrease in mean Medicare spending (adjusted means ratio, 0.62; 95% CI, 0.61-0.64).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Using the population-based linked Surveillance, Epidemiology, and End Results (SEER)-Medicare registry, we selected fee-for-service Medicare beneficiaries with acute or chronic leukemias, multiple myeloma, myeloproliferative neoplasms, myelodysplastic syndrome, and all subtypes of lymphoma who were diagnosed at age 66 years or older, who died between 2008 and 2015 with a cause of death ascribed to the hematologic malignancy, and who had ≥30 days of observed survival since diagnosis (Figure 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "These constructs (Figure 2B) were determined using claims within 30 days before hospice enrollment for those who used hospice services and within 30 days before death for decedents not enrolled in hospice, as previously described.12\nFigure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm.Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Adjusted risk ratios (RR) and means ratios are from multivariable models in the aggregate cohort of all histologies, adjusting for age, sex, race/ethnicity, socioeconomic status, comorbidities, performance status, survival from diagnosis, and temporal trends.From inpatient and outpatient Medicare claims, we then ascertained 3 previously described indicators of aggressive EOL care: death in an acute care hospital, ICU admission in the last 30 days of life, and chemotherapy administration in the last 14 days of life (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Use of hospice services was significantly associated with indicators of higher palliative needs, including prescriptions for opioids (adjusted RR, 1.40; 95% CI, 1.34-1.47), administration of blood transfusions (adjusted RR, 1.32; 95% CI, 1.26-1.38), and mean number of physician visits (adjusted means ratio, 1.21; 95% CI, 1.18-1.24) within 30 days before hospice enrollment or death (supplemental Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "We observed a significant increase in the proportion of beneficiaries enrolled in hospice before death between 2008 and 2015 (P < .001), and a significant decrease in the proportion dying in the acute care hospital (P < .001; Figure 1C).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel C",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "However, there also was a significant increase in patients with ICU admissions at the EOL (P < .001) but no significant change in the proportion receiving chemotherapy at the EOL, in the hospice LOS, or in the median number of days spent in the hospital during the last month of life (Figure 1D).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "These trends were generally consistent across histologies, although we observed a significant increase in the use of chemotherapy at EOL in myeloma (P < .001) and a decreased hospice LOS in leukemia and myeloma (supplemental Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The measures of EOL care differed between hospice enrollees and nonenrollees, with hospice enrollees being consistently less likely to receive aggressive modalities of care at the EOL (Figure 2A-C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "These associations were consistent across major histology groups, as studied in select common specific histologies: acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, and aggressive and indolent non-Hodgkin lymphomas (supplemental Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Furthermore, across all histologies, hospice enrollees had fewer inpatient days in the last 30 days of life and lower Medicare spending (Figure 2D-E), with an average 41% decrease in the number of inpatient days (adjusted means ratio, 0.59; 95% CI, 0.57-0.60) and a 38% decrease in mean Medicare spending (adjusted means ratio, 0.62; 95% CI, 0.61-0.64).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Using the population-based linked Surveillance, Epidemiology, and End Results (SEER)-Medicare registry, we selected fee-for-service Medicare beneficiaries with acute or chronic leukemias, multiple myeloma, myeloproliferative neoplasms, myelodysplastic syndrome, and all subtypes of lymphoma who were diagnosed at age 66 years or older, who died between 2008 and 2015 with a cause of death ascribed to the hematologic malignancy, and who had ≥30 days of observed survival since diagnosis (Figure 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "These constructs (Figure 2B) were determined using claims within 30 days before hospice enrollment for those who used hospice services and within 30 days before death for decedents not enrolled in hospice, as previously described.12\nFigure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm.Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Adjusted risk ratios (RR) and means ratios are from multivariable models in the aggregate cohort of all histologies, adjusting for age, sex, race/ethnicity, socioeconomic status, comorbidities, performance status, survival from diagnosis, and temporal trends.From inpatient and outpatient Medicare claims, we then ascertained 3 previously described indicators of aggressive EOL care: death in an acute care hospital, ICU admission in the last 30 days of life, and chemotherapy administration in the last 14 days of life (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Use of hospice services was significantly associated with indicators of higher palliative needs, including prescriptions for opioids (adjusted RR, 1.40; 95% CI, 1.34-1.47), administration of blood transfusions (adjusted RR, 1.32; 95% CI, 1.26-1.38), and mean number of physician visits (adjusted means ratio, 1.21; 95% CI, 1.18-1.24) within 30 days before hospice enrollment or death (supplemental Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "We observed a significant increase in the proportion of beneficiaries enrolled in hospice before death between 2008 and 2015 (P < .001), and a significant decrease in the proportion dying in the acute care hospital (P < .001; Figure 1C).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel C",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "However, there also was a significant increase in patients with ICU admissions at the EOL (P < .001) but no significant change in the proportion receiving chemotherapy at the EOL, in the hospice LOS, or in the median number of days spent in the hospital during the last month of life (Figure 1D).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "These trends were generally consistent across histologies, although we observed a significant increase in the use of chemotherapy at EOL in myeloma (P < .001) and a decreased hospice LOS in leukemia and myeloma (supplemental Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The measures of EOL care differed between hospice enrollees and nonenrollees, with hospice enrollees being consistently less likely to receive aggressive modalities of care at the EOL (Figure 2A-C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "These associations were consistent across major histology groups, as studied in select common specific histologies: acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, and aggressive and indolent non-Hodgkin lymphomas (supplemental Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Furthermore, across all histologies, hospice enrollees had fewer inpatient days in the last 30 days of life and lower Medicare spending (Figure 2D-E), with an average 41% decrease in the number of inpatient days (adjusted means ratio, 0.59; 95% CI, 0.57-0.60) and a 38% decrease in mean Medicare spending (adjusted means ratio, 0.62; 95% CI, 0.61-0.64).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Using the population-based linked Surveillance, Epidemiology, and End Results (SEER)-Medicare registry, we selected fee-for-service Medicare beneficiaries with acute or chronic leukemias, multiple myeloma, myeloproliferative neoplasms, myelodysplastic syndrome, and all subtypes of lymphoma who were diagnosed at age 66 years or older, who died between 2008 and 2015 with a cause of death ascribed to the hematologic malignancy, and who had ≥30 days of observed survival since diagnosis (Figure 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "These constructs (Figure 2B) were determined using claims within 30 days before hospice enrollment for those who used hospice services and within 30 days before death for decedents not enrolled in hospice, as previously described.12\nFigure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm.Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Adjusted risk ratios (RR) and means ratios are from multivariable models in the aggregate cohort of all histologies, adjusting for age, sex, race/ethnicity, socioeconomic status, comorbidities, performance status, survival from diagnosis, and temporal trends.From inpatient and outpatient Medicare claims, we then ascertained 3 previously described indicators of aggressive EOL care: death in an acute care hospital, ICU admission in the last 30 days of life, and chemotherapy administration in the last 14 days of life (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Use of hospice services was significantly associated with indicators of higher palliative needs, including prescriptions for opioids (adjusted RR, 1.40; 95% CI, 1.34-1.47), administration of blood transfusions (adjusted RR, 1.32; 95% CI, 1.26-1.38), and mean number of physician visits (adjusted means ratio, 1.21; 95% CI, 1.18-1.24) within 30 days before hospice enrollment or death (supplemental Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "We observed a significant increase in the proportion of beneficiaries enrolled in hospice before death between 2008 and 2015 (P < .001), and a significant decrease in the proportion dying in the acute care hospital (P < .001; Figure 1C).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel C",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "However, there also was a significant increase in patients with ICU admissions at the EOL (P < .001) but no significant change in the proportion receiving chemotherapy at the EOL, in the hospice LOS, or in the median number of days spent in the hospital during the last month of life (Figure 1D).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "These trends were generally consistent across histologies, although we observed a significant increase in the use of chemotherapy at EOL in myeloma (P < .001) and a decreased hospice LOS in leukemia and myeloma (supplemental Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The measures of EOL care differed between hospice enrollees and nonenrollees, with hospice enrollees being consistently less likely to receive aggressive modalities of care at the EOL (Figure 2A-C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "These associations were consistent across major histology groups, as studied in select common specific histologies: acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, and aggressive and indolent non-Hodgkin lymphomas (supplemental Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Furthermore, across all histologies, hospice enrollees had fewer inpatient days in the last 30 days of life and lower Medicare spending (Figure 2D-E), with an average 41% decrease in the number of inpatient days (adjusted means ratio, 0.59; 95% CI, 0.57-0.60) and a 38% decrease in mean Medicare spending (adjusted means ratio, 0.62; 95% CI, 0.61-0.64).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Using the population-based linked Surveillance, Epidemiology, and End Results (SEER)-Medicare registry, we selected fee-for-service Medicare beneficiaries with acute or chronic leukemias, multiple myeloma, myeloproliferative neoplasms, myelodysplastic syndrome, and all subtypes of lymphoma who were diagnosed at age 66 years or older, who died between 2008 and 2015 with a cause of death ascribed to the hematologic malignancy, and who had ≥30 days of observed survival since diagnosis (Figure 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "These constructs (Figure 2B) were determined using claims within 30 days before hospice enrollment for those who used hospice services and within 30 days before death for decedents not enrolled in hospice, as previously described.12\nFigure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm.Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Adjusted risk ratios (RR) and means ratios are from multivariable models in the aggregate cohort of all histologies, adjusting for age, sex, race/ethnicity, socioeconomic status, comorbidities, performance status, survival from diagnosis, and temporal trends.From inpatient and outpatient Medicare claims, we then ascertained 3 previously described indicators of aggressive EOL care: death in an acute care hospital, ICU admission in the last 30 days of life, and chemotherapy administration in the last 14 days of life (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Using the population-based linked Surveillance, Epidemiology, and End Results (SEER)-Medicare registry, we selected fee-for-service Medicare beneficiaries with acute or chronic leukemias, multiple myeloma, myeloproliferative neoplasms, myelodysplastic syndrome, and all subtypes of lymphoma who were diagnosed at age 66 years or older, who died between 2008 and 2015 with a cause of death ascribed to the hematologic malignancy, and who had ≥30 days of observed survival since diagnosis (Figure 1A).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "These constructs (Figure 2B) were determined using claims within 30 days before hospice enrollment for those who used hospice services and within 30 days before death for decedents not enrolled in hospice, as previously described.12.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "From inpatient and outpatient Medicare claims, we then ascertained 3 previously described indicators of aggressive EOL care: death in an acute care hospital, ICU admission in the last 30 days of life, and chemotherapy administration in the last 14 days of life (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Use of hospice services was significantly associated with indicators of higher palliative needs, including prescriptions for opioids (adjusted RR, 1.40; 95% CI, 1.34-1.47), administration of blood transfusions (adjusted RR, 1.32; 95% CI, 1.26-1.38), and mean number of physician visits (adjusted means ratio, 1.21; 95% CI, 1.18-1.24) within 30 days before hospice enrollment or death (supplemental Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "We observed a significant increase in the proportion of beneficiaries enrolled in hospice before death between 2008 and 2015 (P < .001), and a significant decrease in the proportion dying in the acute care hospital (P < .001; Figure 1C).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel C",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "However, there also was a significant increase in patients with ICU admissions at the EOL (P < .001) but no significant change in the proportion receiving chemotherapy at the EOL, in the hospice LOS, or in the median number of days spent in the hospital during the last month of life (Figure 1D).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "These trends were generally consistent across histologies, although we observed a significant increase in the use of chemotherapy at EOL in myeloma (P < .001) and a decreased hospice LOS in leukemia and myeloma (supplemental Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The measures of EOL care differed between hospice enrollees and nonenrollees, with hospice enrollees being consistently less likely to receive aggressive modalities of care at the EOL (Figure 2A-C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "These associations were consistent across major histology groups, as studied in select common specific histologies: acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, and aggressive and indolent non-Hodgkin lymphomas (supplemental Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Furthermore, across all histologies, hospice enrollees had fewer inpatient days in the last 30 days of life and lower Medicare spending (Figure 2D-E), with an average 41% decrease in the number of inpatient days (adjusted means ratio, 0.59; 95% CI, 0.57-0.60) and a 38% decrease in mean Medicare spending (adjusted means ratio, 0.62; 95% CI, 0.61-0.64).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Use of hospice services was significantly associated with indicators of higher palliative needs, including prescriptions for opioids (adjusted RR, 1.40; 95% CI, 1.34-1.47), administration of blood transfusions (adjusted RR, 1.32; 95% CI, 1.26-1.38), and mean number of physician visits (adjusted means ratio, 1.21; 95% CI, 1.18-1.24) within 30 days before hospice enrollment or death (supplemental Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "We observed a significant increase in the proportion of beneficiaries enrolled in hospice before death between 2008 and 2015 (P < .001), and a significant decrease in the proportion dying in the acute care hospital (P < .001; Figure 1C).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel C",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "However, there also was a significant increase in patients with ICU admissions at the EOL (P < .001) but no significant change in the proportion receiving chemotherapy at the EOL, in the hospice LOS, or in the median number of days spent in the hospital during the last month of life (Figure 1D).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "These trends were generally consistent across histologies, although we observed a significant increase in the use of chemotherapy at EOL in myeloma (P < .001) and a decreased hospice LOS in leukemia and myeloma (supplemental Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The measures of EOL care differed between hospice enrollees and nonenrollees, with hospice enrollees being consistently less likely to receive aggressive modalities of care at the EOL (Figure 2A-C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "These associations were consistent across major histology groups, as studied in select common specific histologies: acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, and aggressive and indolent non-Hodgkin lymphomas (supplemental Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Furthermore, across all histologies, hospice enrollees had fewer inpatient days in the last 30 days of life and lower Medicare spending (Figure 2D-E), with an average 41% decrease in the number of inpatient days (adjusted means ratio, 0.59; 95% CI, 0.57-0.60) and a 38% decrease in mean Medicare spending (adjusted means ratio, 0.62; 95% CI, 0.61-0.64).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  }
]